# US 8,278,328 B2 · Compounds which have activity at M1 receptor and their uses in medicine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,328 B2
- Document ID: US8278328B2
- Status: Granted
- Kind: B2
- Application number: 12/678,347
- Filed: 2008-09-18
- Published: 2010-08-12
- Granted: 2012-10-02
- Earliest claimed: 2007-09-20
- Assignees: Glaxo Group Limited
- Inventors: David Gwyn Cooper; Ian Thomson Forbes; Vincenzo Garzya; Dale James Johnson; Graeme Irvine Stevenson; Paul Adrian Wyman
- Web page: https://patentgrep.com/patent/US8278328B2

## CPC

- C07D 498/04: Ortho-condensed systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 15/10: for impotence
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 209/34: in position 2
- C07D 215/227: only one oxygen atom which is attached in position 2
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

## Claims

### Claim 1

A compound of formula (I) or a salt thereof:
wherein
R4, R5 and R6 are independently selected from hydrogen, halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, cyano, C1-6alkylsulfonyl, C1-6alkylsulfonyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C1-6alkoxy, C1-6alkoxy substituted with one or more fluorine atoms, C1-6alkanoyl, —C(═NOC1-6alkyl)C1-6alkyl,
—C1-6alkoxyC1-6alkyl, and —C(O)NRaRb;
Ra and Rb are each independently H or C1-6 alkyl, or together with the nitrogen atom to which they are attached form a five or six membered ring;
ring A represents a benzene ring, or a 6-membered aromatic heterocylic ring containing one or two nitrogen atoms;
R is selected from C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-4-alkyl, C1-6alkyloxyC1-6alkyl, C3-6cycloalkyloxyC1-6alkyl and C3-6cycloalkylC1-4-alkyloxyC1-6alkyl, wherein any alkyl or cycloalkyl group is optionally substituted by one or more fluorine atoms;
Q is selected from hydrogen and C1-6alkyl; and
Y is selected from O, S, CH2 optionally substituted with one or two fluorine atoms or optionally substituted with one or two methyl groups, CH2CH2, OCH2, and CH2O.

### Claim 2 (depends on 1)

A compound as claimed in claim 1 wherein R6 is cyano.

### Claim 3 (depends on 1)

A compound as claimed in claim 1 wherein R is C3-6cycloalkylC1-4-alkyl.

### Claim 4 (depends on 1)

A compound as claimed in claim 1 wherein Y is O.

### Claim 5 (depends on 1)

A compound as claimed in claim 1 wherein A is a benzene ring.

### Claim 6

A compound selected from the group consisting of:
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-1-Methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carbonitrile;
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-6-fluoro-5-methyl-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-5-(methylsulfonyl)-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-5-(ethylsulfonyl)-1,3-benzoxazol-2(3H)-one;
5-Fluoro-3-{1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-5-fluoro-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-5-(methyloxy)-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-5-methyl-1,3-benzoxazol-2(3H)-one;
4-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-6-methyl-2H-1,4-benzoxazin-3(4H)-one;
3-[1-(cis-1-Methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carbonitrile;
6-Methyl-1-{1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,3-dihydro-2H-indol-2-one;
3-{1-[trans-4-Ethoxy-1-methylcyclohexyl]-4-piperidinyl}-7-fluoro-5-methyl-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-4-Ethoxy-1-methylcyclohexyl]-4-piperidinyl}-6,7-difluoro-5-methyl-1,3-benzoxazol-2(3H)-one;
5-Methyl-3-{1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-5,7-difluoro-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-5-[(trifluoromethyl)oxy]-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-5,6-difluoro-1,3-benzoxazol-2(3H)-one;
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-5-(trifluoromethyl)-1,3-benzoxazol-2(3H)-one;
6-Methyl-1-{1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1,3-dihydro-2H-indol-2-one;
3-{1-[trans-1-Methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carbonitrile;
1-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-6-methyl-1,3-dihydro-2H-indol-2-one;
3-{1-[trans-1-Methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-5-(methylsulfonyl)-1,3-benzoxazol-2(3H)-one;
1-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-7-methyl-3,4-dihydro-2(1H)-quinolinone;
3,3,6-Trimethyl-1-{1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,3-dihydro-2H-indol-2-one;
6-Methyl-1-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-1,3-dihydro-2H-indol-2-one;
3-{1-[trans-1-Methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-5-[(trifluoromethyl)sulfonyl]-1,3-benzoxazol-2(3H)-one;
6-Methyl-3-{1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-5-(methylsulfonyl)-1,3-benzoxazol-2(3H)-one;
6-Methyl-5-(methylsulfonyl)-3-{1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,3-benzoxazol-2(3H)-one;
5-Methyl-3-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-2-oxo-2,3-dihydro-1,3-benzoxazole-6-carbonitrile;
5-(Difluoromethoxy)-3-{1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-1,3-benzoxazol-2(3H)-one;
5-Methyl-3-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-1,3-benzoxazol-2(3H)-one;
3-[1-(trans-1-Methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-5-(methyloxy)-1,3-benzoxazol-2(3H)-one;
3-(1-{trans-4-[(Cyclopropylmethyl)oxy]-1-methylcyclohexyl}-4-piperidinyl)-5-(methylsulfonyl)-1,3-benzoxazol-2(3H)-one;
3-(1-{trans-1-Methyl-4-[(1-methylethyl)oxy]cyclohexyl}-4-piperidinyl)-5-(methylsulfonyl)-1,3-benzoxazol-2(3H)-one;
3-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-5-(trifluoromethyl)-1,3-benzoxazol-2(3H)-one;
6-Fluoro-5-methyl-3-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]-oxy}cyclohexyl)-4-piperidinyl]-1,3-benzoxazol-2(3H)-one;
7-Fluoro-3-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carbonitrile;
7-Fluoro-5-methyl-3-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-1,3-benzoxazol-2(3H)-one;
6-Fluoro-3-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carbonitrile;
3-[1-(trans-1-Methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-5-(methylsulfonyl)-1,3-benzoxazol-2(3H)-one;
3-[1-(trans-1-Methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-5-[(methyloxy)methyl]-1,3-benzoxazol-2(3H)-one;
1-[1-(trans-1-Methyl-4-[2-(methoxyethoxy)cyclohexyl]-4-piperidinyl]-6-(methoxymethyl)-1,3-dihydro-2H-indol-2-one;
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carboxamide;
3-[1-(trans-1-Methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carboxamide;
5-Acetyl-3-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-1,3-benzoxazol-2(3H)-one;
3-[1-(trans-1-Methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-5-[N-(methyloxy)ethanimidoyl]-1,3-benzoxazol-2(3H)-one;
1-[1-(trans-4-{2-Methoxyethoxy}cyclohexyl)-4-piperidinyl]-2-oxo-2,3-dihydro-1H-indole-6-carbonitrile;
1-[1-(cis-4-{2-Methoxyethoxy}cyclohexyl)-4-piperidinyl]-2-oxo-2,3-dihydro-1H-indole-6-carbonitrile;
3-{1-[trans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-5-fluoro-1,3-benzoxazol-2(3H)-one; and
3-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-5-methyl[1,3]oxazolo[4,5-b]pyridin-2(3H)-one;
and salts thereof.

### Claim 7 (depends on 1)

A compound as claimed in claim 1 wherein the salt is a pharmaceutically acceptable salt.

### Claim 8 (depends on 7)

A pharmaceutical composition comprising a compound as claimed in claim 7 and a pharmaceutically acceptable carrier.
